Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease

Abstract

In all, 17 consecutive patients in hematological complete remission (HCR) of acute promyelocytic leukemia (APL) received allogeneic stem cell transplantation (SCT) from an HLA-identical sibling and were monitored by reverse transcriptase polymerase chain reaction of PML/RARα prior and after transplant. Median age was 31 years (range 3–50 years). At 10 years, the actuarial probabilities of nonrelapse mortality, relapse and disease-free survival were 32% (95% CI: 8–56%), 33% (95% CI: 6–60%) and 46% (95% CI: 22–70%). Six patients tested PCR +ve (1st HCR n=2; 2nd HCR n=3; 3rd HCR n=1) and 11 PCR −ve (2nd HCR n=11) pre-SCT. Of the six patients PCR +ve, two showed early persistence of PCR positivity and converted to sustained PCR negativity after CSA withdrawal (one died of secondary tumor in molecular remission and one is alive in relapse), while four converted to PCR −ve rapidly (one died of the underlying disease and three are in molecular remission). Of the 11 patients PCR −ve pre-SCT, six died (four of transplant-related mortality, one of relapse and one after heart transplantation) and five are alive, four in molecular remission and one is in relapse. Allogeneic SCT seems a valid option for advanced APL, particularly for the poor prognostic group of patients with pre-SCT molecularly persistent disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukaemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.

    Article  CAS  Google Scholar 

  2. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M . Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490.

    Article  CAS  Google Scholar 

  3. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.

    CAS  PubMed  Google Scholar 

  4. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.

    Article  CAS  Google Scholar 

  5. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell Jr RP . All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40 (Suppl): S25–S29.

    Article  Google Scholar 

  6. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiroka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78–85.

    Article  CAS  Google Scholar 

  7. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93: 4131–4143.

    CAS  PubMed  Google Scholar 

  8. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999; 94: 3015–3021.

    CAS  PubMed  Google Scholar 

  9. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.

    CAS  PubMed  Google Scholar 

  10. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362–1370.

    Article  CAS  Google Scholar 

  11. Diverio D, Rossi V, Avvisati G, De Santis S, Pestilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukaemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ Trial. Blood 1998; 92: 784–789.

    CAS  PubMed  Google Scholar 

  12. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.

    CAS  PubMed  Google Scholar 

  13. Nabhan C, Metha J, Tallman MS . The role of bone marrow transplantation in acute promyelocytic leukaemia. Bone Marrow Transplant 2001; 28: 219–226.

    Article  CAS  Google Scholar 

  14. Mandelli F, Labopin M, Granena A, Iriondo A, Prentice G, Bacigalupo A et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group of Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1994; 14: 293–298.

    CAS  PubMed  Google Scholar 

  15. Glucksberg H, Storb R, Fefer A . Clinical manifestations of graft-versus-host-disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  16. Shulman HM, Sullivan KM, Weiden PL, Sale GE, Hackman R, Tsoi MS, Storb R et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  17. Chomczynsky P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate–phenol chloroform extraction. Ann Biochem 1987; 162: 156–159.

    Google Scholar 

  18. Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F et al. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214–1216.

    CAS  PubMed  Google Scholar 

  19. Sanz M, Arcese W, De La Rubia J, Lo Coco F, Labopin M, Bacigalupo A et al. Stem cell transplantation (SCT) for acute promyelocytic leukaemia in the ATRA era: a survery of the European Blood and Marrow Transplantation Group (EBMT). Blood19 Refs. cited in the ref. list, but only 18 cited in text, pl. check. 2000; 96(Suppl. 1): 522a (Abstract 2247).

    Google Scholar 

Download references

Acknowledgements

This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro), AIL (Associazione Italiana contro le Leucemie), MIUR (Ministero della Università e della Ricerca Scientifica e Tecnologica), CNR (Consiglio Nazionale delle Ricerche) and Ministero della Salute.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lo-Coco, F., Romano, A., Mengarelli, A. et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 17, 1930–1933 (2003). https://doi.org/10.1038/sj.leu.2403078

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403078

Keywords

This article is cited by

Search

Quick links